LT2448968T - Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus - Google Patents

Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus

Info

Publication number
LT2448968T
LT2448968T LTEP10739701.0T LT10739701T LT2448968T LT 2448968 T LT2448968 T LT 2448968T LT 10739701 T LT10739701 T LT 10739701T LT 2448968 T LT2448968 T LT 2448968T
Authority
LT
Lithuania
Prior art keywords
terminaltruncated
protofibrils
amyloid
oligomers
antibodies selective
Prior art date
Application number
LTEP10739701.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda SÖDERBERG
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of LT2448968T publication Critical patent/LT2448968T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP10739701.0T 2009-06-29 2010-06-29 Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus LT2448968T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (1)

Publication Number Publication Date
LT2448968T true LT2448968T (lt) 2021-05-10

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10739701.0T LT2448968T (lt) 2009-06-29 2010-06-29 Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP2448968B1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN103459421B (zh) * 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
EP3325506A1 (en) 2015-07-21 2018-05-30 BioArctic AB Method for treatment of traumatic brain injury targeting aggregated peptides
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020023530A2 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
EP3998280A4 (en) * 2019-07-08 2023-06-21 TERUMO Kabushiki Kaisha HYBRIDOME AND METHOD FOR PRODUCTION, MONOCLONAL ANTIBODY AND METHOD FOR PRODUCTION
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
HRP20250812T1 (hr) 2020-06-26 2025-09-12 Bioarctic Ab Antitijela koja vežu alfa-sinuklein protofibril
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
CA3230148A1 (en) 2021-08-30 2023-03-09 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ATE283285T1 (de) * 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
AU2001268005A1 (en) * 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005100402A1 (en) * 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
AU2008322523B2 (en) * 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
ES2709048T3 (es) * 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína

Also Published As

Publication number Publication date
PT2448968T (pt) 2021-04-30
EP3892633A1 (en) 2021-10-13
JP2012532094A (ja) 2012-12-13
SI2448968T1 (sl) 2021-07-30
AU2010267640B2 (en) 2015-03-05
HUE053949T2 (hu) 2021-08-30
US20230295283A1 (en) 2023-09-21
HRP20210611T1 (hr) 2021-05-28
CA2765602A1 (en) 2011-01-06
DK2448968T3 (da) 2021-04-12
EP2448968A1 (en) 2012-05-09
SMT202100237T1 (it) 2021-05-07
JP6884025B2 (ja) 2021-06-09
ES2864049T3 (es) 2021-10-13
CY1124034T1 (el) 2022-05-27
CA2765602C (en) 2021-05-25
EP2448968B1 (en) 2021-01-27
PL2448968T3 (pl) 2021-09-13
WO2011001366A1 (en) 2011-01-06
JP2017197531A (ja) 2017-11-02
AU2010267640A1 (en) 2012-01-19
US20120100129A1 (en) 2012-04-26
JP2019218362A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
SI2448968T1 (sl) Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
ZA201202299B (en) Method for decreasing immunigenicity
GB0905140D0 (en) Method
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
GB0902476D0 (en) Method
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
ZA201106800B (en) Method for purifying recombinant fsh
HRP20150775T1 (en) Method for preparing hypoallergens
GB0901444D0 (en) Method
GB0903316D0 (en) Method
IL208514A0 (en) Process for preparing substituted biphenylanilides
GB0905367D0 (en) Method
IL217192A0 (en) Biorefinery method
ZA201203155B (en) Method for isolating methylglycinenitrile-n,n-diacetonitrile
HUE038182T2 (hu) Eljárás faforgács szárítására
GB0902034D0 (en) Method
GB0904946D0 (en) Method
GB0900560D0 (en) Method
EP2433942A4 (en) PROCESS FOR THE PREPARATION OF D-BIOTIN
GB0903026D0 (en) Novel method
GB0905332D0 (en) Method
GB2476082B (en) Improved base station architecture
IL199690A0 (en) Hanger for fhelf
GB0922292D0 (en) Novel Method